Postop inflammation & pain drug launched

Article

Durezol 0.05% (difluprednate ophthalmic emulsion; Sirion Therapeutics Inc), a topical corticosteroid to treat postoperative ocular inflammation and pain, is now commercially available, following FDA approval in June 2008.

Durezol 0.05% (difluprednate ophthalmic emulsion; Sirion Therapeutics Inc), a topical corticosteroid to treat postoperative ocular inflammation and pain, is now commercially available, following FDA approval in June 2008.

Durezol has demonstrated, during trials held in Japan and the US, an effective reduction in pain and inflammation amongst subjects suffering inflammation of ≥10 anterior chamber cells, without increasing intraocular pressure (IOP) outside of normal levels. Durezol is administered to the conjunctival sac four times daily for two weeks (beginning 24 hours after surgery) and twice daily for a further week.

Sirion is currently conducting Phase III trials to evaluate Durezol in other ocular conditions, including anterior uveitis. Results of a Phase IIIb trial assessing the efficacy of the drug for the treatment of postoperative ocular inflammation and pain when administered 24 hours prior to surgery have shown that preoperative administration of Durezol is more effective than placebo for reducing ocular pain as early as three or four days after surgery; superiority was maintained until Day 28, regardless of whether Durezol was dosed two or four times daily.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.